Wells et al developed a score for the myelodysplastic syndrome (MDS) based on flow cytometric findings. One component involves the presence of markers on monocytoid cells. The authors are from the Hematologics, Inc, Fred Hutchinson Cancer Research Center, and the University of Washington, Seattle.
Parameters:
(1) granularity
(2) CD11b expression
(3) HLA-DR expression
(4) CD13 expression
(5) CD16 expression
(6) CD56 expression
(7) CD33 expression
(8) CD14 expression
(9) CD34 expression
(10) expression of other lymphoid markers not including CD4 (CD19, CD5, CD7)
|
Parameters |
Finding |
Points |
|
granularity |
normal |
0 |
|
|
abnormal |
1 |
|
CD11b and HLA-DR expression |
CD11b positive and heterogenous HLA-DR |
0 |
|
|
other |
1 |
|
CD13 and CD16 expression |
both coexpressed |
0 |
|
|
either or both not expressed |
1 |
|
CD56 |
absent |
0 |
|
|
present |
1 |
|
CD14 and CD33 expression |
both coexpressed |
0 |
|
|
either or both not expressed |
1 |
subscore for initial abnormalities =
= SUM(points for all 5 measures)
|
Initial Abnormalities |
CD34 Expression |
Other Lymphoid Markers |
Points for Monocytic Abnormalities |
|
0 |
0 |
0 |
0 |
|
1 |
0 |
0 |
1 |
|
2 or 3 |
0 |
0 |
2 |
|
4 or 5 |
0 |
0 |
3 |
|
0 |
1 |
0 |
2 |
|
0 |
0 |
1 |
2 |
|
1 or more |
1 |
0 |
3 |
|
1 or more |
0 |
1 |
3 |
|
1 or more |
1 |
1 |
3 |
Specialty: Hematology Oncology, Clinical Laboratory
ICD-10: ,
